Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection

Brief description of study

There are currently no approved effective therapeutic agents available for the treatment of COVID, and the availability of an effective antiviral agent with a favorable benefit/risk profile would address a serious unmet medical need for the treatment of patients with COVID. The purpose of this research study is to provide expanded access of Remdesivir (RDV) for the treatment of SARS-CoV2 infection. Remdesivir (RDV) is considered an investigational drug. Investigational means that the Food and Drug Administration (FDA) has not yet approved the drug for this use.


Clinical Study Identifier: s20-00620
Principal Investigator: Tshering Dorjee Amdo.
Other Investigator: Stephanie Sterling.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.